Skin cancer is among the most costly of all cancers to treat for the Medicare population
Skin cancer is among the most costly of all cancers to treat for the Medicare population
复制标题
DOI：
10.1067/mjd.2003.186
复制
发表时间：
2003-03-01
影响因子：
13.8
通讯作者：
Chen, GJ
中科院分区：
文献类型：
--
作者：
Housman, TS;Feldman, SR;Chen, GJ
背景：与其他恶性肿瘤相比，非黑色素瘤皮肤癌（NMSC）的发病率和死亡率要低得多。然而，NMSC比其他恶性肿瘤更常见。管理NMSC的成本还没有被assessed.Objective：我们研究的目的，vas，以确定在其他癌症的Medicare population.Design的NMSC管理的成本排名：代表性的医疗保险A部分和B索赔数据从医疗保险目前的受益人调查，1992年至1995年。与癌症费用有关的索赔是使用国际疾病分类第九修订版临床修改代码确定的。权重被应用到获得全国代表性的estimates.Results：平均医疗保险支出癌症管理是每年13亿美元。医疗保险费用最高的5种癌症是肺和支气管、前列腺、结肠和直肠、乳腺和NMSC。使用医疗保险治疗所有癌症的每位患者的平均年费用为17094美元。肺和支气管，结肠和直肠，乳腺癌，前列腺癌是11至19倍，每个受影响的患者比NMSC.Conclusion：除了分类癌症的病例数和死亡人数，治疗的经济影响也可以用来优先考虑不同的恶性肿瘤。这样一个计划对NMSC的排名远远高于死亡统计数字。鉴于其已经很高的发病率和不断上升的发病率，医疗保险的NMSC护理费用可能会增加。然而，为了保持NMSC的成本效益管理，必须保持其管理的当前低患者成本。
Background: Compared with other malignancies, nonmelanoma skin cancer (NMSC) is associated with much less morbidity and mortality. NMSC is, however, far more common than other malignancies. The cost of managing NMSC has not been assessed.Objective: The purpose of our study,,vas to determine where the cost of NMSC management ranks among other cancers in the Medicare population.Design: Representative Medicare part A and B claims data were obtained from the Medicare current beneficiary survey, 1992 to 1995. Claims associated with cancer costs were identified using the International Classification of Diseases, Ninth Revision, Clinical Modification codes. Weights were applied to obtain nationally representative estimates.Results: Average Medicare expenditure on cancer management was $13 billion per year. The 5 most costly cancers to Medicare were lung and bronchus, prostate, colon and rectum, breast, and NMSC. The mean annual cost per patient using Medicare for all cancers vas $17,094. Malignancies of lung and bronchus, colon and rectum, breast, and prostate were 11 to 19 times more costly per affected patient than NMSC.Conclusion: In addition to classifying cancers by number of cases and number of deaths, the financial impact of treatment can also be used to prioritize different malignancies. Such a scheme ranks NMSC far higher than would death statistics. In light of its already high and rising incidence, the cost of NMSC care to Medicare is likely to increase. However, to maintain the cost-effective management of NMSC, it is essential to preserve the current low per-patient cost of its management.